Shots:

• The EMA’s CHMP has adopted a positive opinion of pemigatinib for the treatment of adults with unresectable locally advanced or metastatic cholangiocarcinoma with documented FGF/FGFR status- after at least one line of ST
• The CHMP opinion is based on P-II FIGHT-202 and patients enrolled into one of three cohorts – cohort a (FGFR2 fusions or rearrangements)- cohort b (other FGF/FGFR genetic alterations) or cohort c (no FGF/FGFR genetic alterations)
• Pemigatinib will be the 1st targeted therapy indicated in the EU if approved for this indication

 ­ Ref: Businesswire | Image: Incyte